PubMed=9241074; DOI=10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U
Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C., Barber J.R., Jolly D.J., Seigler H.F.
A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.
Cancer 80:401-412(1997)

PubMed=11520076; DOI=10.1006/cimm.2001.1809
Zennadi R., Abdel-Wahab Z., Seigler H.F., Darrow T.L.
Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
Cell. Immunol. 210:96-105(2001)

PubMed=19147755; DOI=10.1158/1078-0432.CCR-08-1916
Augustine C.K., Yoo J.S., Potti A., Yoshimoto Y., Zipfel P.A., Friedman H.S., Nevins J.R., Ali-Osman F., Tyler D.S.
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Clin. Cancer Res. 15:502-510(2009)